Varicella
Conditions
Brief summary
This is Phase 4 clinical trial of live attenuated varicella vaccines manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd .The purpose of this study is to evaluate the protective effect of varicella vaccine in children aged 1-12 years and the correlation between varicella antibody and protective effect,to evaluate the immunogenicity and safety of varicella vaccine in children aged 1-12 years.
Detailed description
This study is Phase Ⅳ clinical trial.The experimental vaccine manufactured by Sinovac(Dalian) Vaccine Technology Co., Ltd.This clinical trial consists of four parts,and A total of 45400 subjects will be enrolled. Study 1,45000 subjects including 15000 subjects aged 1-3 years with no history of varicella vaccination ,15000 subjects aged 4-6 years with a history of 1 dose of varicella vaccine,15000 subjects aged 7-12 years with a history of 1 dose of varicella vaccine will be enrolled to evaluate protective effect of varicella vaccine. There will be 7500 subjects in the experimental group and 7500 in the control group in each age group.And subjects who voluntarily receive varicella vaccine will be included in the experimental group and other subjects will be included in the control group.All subjects in the experimental group will receive one dose of varicella vaccine. Study 2,400 healthy children including 100 subjects aged 1-3 years with no history of varicella ,150 subjects aged 4-6 years(50 children with no history of varicella vaccination and 100 children with a history of one dose of varicella vaccine),150 subjects aged 7-12 years (50 children with no history of varicella vaccination and 100 children with a history of one dose of varicella vaccine),each subject will receive one or two doses (0,3 months) of varicella vaccine. Study 3,30000 subjects from study 1 will be enrolled to conduct safety observation study,all adverse events of all subjects will be collected. Study 4,Herpes fluid collected from study 1 varicella cases will be used to conduct etiological study on the pathogenic strains of varicella cases.
Interventions
BIOLOGICALLive attenuated varicella vaccine
The live attenuated varicella vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd. Live attenuated varicella-virus in 0.5 mL injection water with sucrose,sodium glutamate,sodium chloride,potassium chloride, sodium dihydrogen phosphate, potassium dihydrogen phosphate per injection.The routine of administration is intramuscular injection into deltoid region of the lateral upper arm.
Sponsors
Sinovac (Dalian) Vaccine Technology Co., Ltd.
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
1 Years to 12 Years
Healthy volunteers
No
Inclusion criteria
Study 1: Inclusion criteria for a protective effect study of varicella vaccine: * Healthy children aged 1-12 years without a history of varicella; * The subjects and/or guardians can understand and voluntarily sign the informed consent form (For subjects aged 8 years and above, both subjects and guardians need to sign the informed consent form); Study 2: Inclusion criteria for immunogenicity and safety evaluation of varicella vaccine: * Healthy children aged 1-12 years without a history of varicella; * The subjects and/or guardians can understand and voluntarily sign the informed consent form (For subjects aged 8 years and above, both subjects and guardians need to sign the informed consent form); * The subjects and their guardians voluntarily participate in the study and are able to follow all study procedures; * Proven legal identity. Study 3: Inclusion criteria for safety evaluation of mass vaccination of varicella vaccine : * Healthy children aged 1-12 years without a history of varicella; * The subjects and/or guardians can understand and voluntarily sign the informed consent form (For subjects aged 8 years and above, both subjects and guardians need to sign the informed consent form); * The subjects and their guardians voluntarily participate in the study and are able to follow all study procedures; * Proven legal identity; * Subjects'guardians can fill in adverse events using mobile apps; Study 4: Inclusion criteria for etiological study on the pathogenic strains of varicella cases: * Varicella cases among study 1 enrolled subjects who signed informed consent for biological samples collection.
Exclusion criteria
* Received two doses of varicella vaccine from other manufacturers(applied to study 1
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The incidence density | 42 days after vaccination | The incidence density will be calculated by the number of confirmed cases of varicella at 42 days after vaccination. |
| The protection rate | 42 days after vaccination | The protection rate will be calculated by the number of confirmed cases of varicella at 42 days after vaccination. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| GMT of varicella antibody | 42 days after varicella vaccination | GMT of varicella antibody at 42 days after varicella vaccination. |
| GMI of varicella antibody | 42 days after varicella vaccination | GMI of varicella antibody at 42 days after varicella vaccination. |
| Positive rates of varicella antibody | 42 days after varicella vaccination | Positive rate of varicella antibody at 42 days after varicella vaccination. |
| Immunogenicity index-GMT of varicella antibody | 4 months after varicella vaccination | GMT of varicella antibody at 4 months after varicella vaccination. |
| Immunogenicity index-GMI of varicella antibody | 4 months after varicella vaccination | GMI of varicella antibody at 4 months after varicella vaccination. |
| Incidence of adverse events, serious adverse events and adverse reactions | 42 days after varicella vaccination. | The incidence of adverse events, serious adverse events and adverse reactions at 42 days after varicella vaccination. |
| Safety index-Incidence of adverse events, serious adverse events and adverse reactions | 3 months after varicella vaccination | The incidence of adverse events, serious adverse events and adverse reactions in 3 months after varicella vaccination. |
| Safety index-incidence of adverse events, serious adverse events and adverse reactions | 6 months after varicella vaccination | The incidence of adverse events, serious adverse events and adverse reactions in 6 months after varicella vaccination. |
| Safety index- incidence of adverse events, serious adverse events and adverse reactions | 9 months after varicella vaccination | The incidence of adverse events, serious adverse events and adverse reactions in 9 months after varicella vaccination. |
| The incidence of adverse events, serious adverse events and adverse reactions | 14 days after varicella vaccination | The incidence of adverse events, serious adverse events and adverse reactions at 14 days after varicella vaccination. |
| Immunogenicity index- positive rates | 4 months after varicella vaccination | Positive rates of varicella antibody at 4 months after varicella vaccination. |
Countries
China
Outcome results
None listed